Alnylam Pharmaceuticals (ALNY) EBITDA Margin Growth (3y) (2012 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) EBITDA Margin Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | -347.00 |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -15,844.00 |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | -377.00 |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | -204.00 |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 7,045.00 |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -1,934.00 |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 9,003.00 |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -2,825.00 |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 30,461.00 |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -56,192.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9,003.00 |
| Mar 31, 2026 | 6,993.00 |
| Dec 31, 2025 | 6,830.00 |
| Sep 30, 2025 | 12,709.00 |
| Jun 30, 2025 | 8,317.00 |
| Mar 31, 2025 | 12,906.00 |
| Dec 31, 2024 | 5,753.00 |
| Sep 30, 2024 | 8,147.00 |
| Jun 30, 2024 | 7,364.00 |
| Mar 31, 2024 | 9,611.00 |
| Dec 31, 2023 | 9,227.00 |
| Sep 30, 2023 | 20,743.00 |
| Jun 30, 2023 | 11,918.00 |
| Mar 31, 2023 | 16,435.00 |
| Dec 31, 2022 | 35,954.00 |
| Sep 30, 2022 | 21,110.00 |
| Jun 30, 2022 | 44,314.00 |
| Mar 31, 2022 | 49,823.00 |
| Dec 31, 2021 | 97,241.00 |
| Sep 30, 2021 | 1.22 Mn |